Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The ERG rearrangement seemed to be frequently expressed in patients with relatively younger age and lower Gleason score and infrequently expressed in PCa with the IDC-P. PCa with positive ERG were less frequently to progress to CRPC, but there was no prognostic significance of ERG expression.
|
30900303 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of our project was to test the impact of adjuvant radiotherapy (ART) in patients with localized to locally advanced prostate cancer (PC) and IDC-P.
|
31018850 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTEN loss was significantly (P < 0.05) associated with increasing GG, poorly formed glands (74% of total cases with loss vs 49% of intact), and three well-validated unfavorable pathological features: intraductal carcinoma of the prostate (IDC-P) (69% of total cases with loss vs 12% of intact), cribriform Gleason pattern 4 (38% of total cases with loss vs 10% of intact) and stromogenic PCa (23% of total cases with loss vs 6% of intact).
|
31111513 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fifteen consecutive men with ISUP GG 2/3 (Gleason score 3+4 = 7 [N = 4], 4+3 = 7 [N = 11]) PCa with IDC-P diagnosed at radical prostatectomy were compared with: 1) ISUP GG 2/3 PCa without IDC-P (matched for percentage Gleason pattern 4), and 2) ISUP GG 4 and 5 (Gleason score 8/9) PCa without IDC-P.
|
30585372 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the association of IDC-P in prostate biopsy (PBx) with several pathological features after radical prostatectomy (RP) and its prognostic value in high-risk PCa.
|
31710002 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated whether intraductal carcinoma of the prostate (IDC-P) confirmed by needle biopsy is an adverse prognostic parameter for progression-free survival (PFS) and cancer-specific survival (CSS) in patients with high-risk prostate cancer.
|
29094384 |
2018 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
CR/IDC growth is associated with increased genomic instability clustering to genetic regions involved in aggressive prostate cancer.
|
29295717 |
2018 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, we suggest that lamin A/C might serve as a reliable epithelial biomarker for the distinction of PC cell differentiation and might also be a fundamental factor in the occurrence of EMT or MET in PC.
|
29665450 |
2018 |
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To demonstrate the response of IDC-P to ADT, we established PDXs from seven patients with familial and/or high-risk sporadic prostate cancer.
|
28977728 |
2018 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 10-year prostate cancer-specific survival was 69% for patients with IDC-P on diagnostic needle biopsy and 89% for patients without IDC-P (Log rank P-value < 0.005).
|
28240424 |
2017 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
IDC-P was associated with a 3-fold increase in prostate cancer-specific mortality relative to non-IDC-P (hazard ratio = 3.0, 95% CI: 1.5-5.7; P<0.01).
|
28919182 |
2017 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
From our data we conclude that the Lamin C : Lamin A mRNA ratio is increased in breast cancer and that this mRNA ratio may be of diagnostic use in all clinical stages of breast cancer and, possibly, also in liver, lung, thyroid, colon, ovary and prostate cancers.
|
26732077 |
2016 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
PDXs from BRCA2 tumours showed increased incidence of IDC-P compared with sporadic PCa (p=0.015).
|
25154392 |
2015 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Localization of prenylated proteins (H-Ras, prelamin A/C, and Rab5a) was observed in poorly differentiated PCa (PC-3) and well-differentiated PCa (LNCaP) cells.
|
26181205 |
2015 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
IDC-P is an aggressive phenotype of prostate cancer and predicts poor response to ADT, CT, and external beam radiation.
|
22949099 |
2013 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
IDC-P is an uncommon finding in prostate biopsies, and is even rarer as an isolated finding without concomitant prostate cancer in biopsies.
|
24018805 |
2013 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human CaP cell lines frequently have nuclear lobulations, which are enriched in A-type lamins but lack B-type lamins and have been defined as lamin B-deficient microdomains (LDMDs).
|
22025297 |
2012 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of the present study was to analyze the genetic relationship between benign prostatic tissue, PIN, invasive cancer, IDC-P, and extracapsular tumor tissue to get further information about the role of IDC-P in the development of prostate cancer.
|
18383208 |
2008 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
IDC-P and Gleason grade 4 cancer represent late but possibly separate events in prostate cancer evolution.
|
10951489 |
2000 |